Abstract
Tuberculosis (TB) remains a main hurdle for national programs due to increase in drug resistance to antitubercular drugs. World Health Organization (WHO)-endorsed Line Probe Assay, Genotype MTBDRsl Ver 2.0, gives opportunity for rapid diagnosis and molecular characterization of different mutations in drug targets of fluoroquinolone (FQ) and second-line injectable drugs (SLID). We, retrospectively, analyzed the data of Genotype MTBDRsl Ver 2.0 from January 2018 to June 2018. A total of 863 isolates of Mycobacterium tuberculosis, 687 rifampicin resistant and 176 isoniazid resistant only, were screened for drug resistance in FQ and SLID. All the isolates were tested for Genotype MTBDRsl Ver 2.0 according to the manufacturer’s instructions. The FQ and SLID resistance were detected in 295 (34.2%) and 70 (8.1%) isolates, respectively. Among newly diagnosed and followup rifampicin-resistant TB (RR TB) patients, the FQ resistance was 25.8% and 44.5%, respectively. The most common mutation (42.7%) in FQ-resistant isolates was MUT3C in gyrA gene. Both SLID and FQ resistance were detected in 59 (6.8%) RR TB isolates. The mono SLID resistance was detected in 12 (1.7%) isolates of RR TB. Genotype MTBDRsl Ver 2.0 assay is a rapid and important tool for the diagnosis and molecular characterization of second-line drug resistance under programmatic conditions.
Article PDF
Avoid common mistakes on your manuscript.
References
World Health Organization. Global tuberculosis report. Geneva: WHO; 2017. Available from: http://apps.who.int/iris/bitstream/handle/10665/259366/9789241565516-eng.pdf?sequence=1
World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: WHO; 2014. Available from: http://apps.who.int/iris/bitstream/handle/10665/130918/9789241548809_eng.pdf?sequence=1
World Health Organization. The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs. WHO Policy guidance. Geneva: WHO; 2016. Available from: http://www.who.int/tb/WHOPolicyStatementSLLPA.pdf.
Theron G, Peter J, Richardson M, Barnard M, Donegan S, Warren R, et al. The diagnostic accuracy of the GenoType® MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs. Cochrane Database Syst Rev 2014;CD010705.
Hain Lifescience. GenoType MTBDRsl Ver 2.0 instructions for use. Document IFU-317A-01. Nehren, Germany: Hain Life Science; 2015.
Gardee Y, Dreyer AW, Koornhof HJ, Omar SV, da Silva P, Bhyat Z, et al. Evaluation of the GenoType MTBDRsl Version 2.0 assay for second-line drug resistance detection of Mycobacterium tuberculosis isolates in South Africa. J Clin Microbiol 2017;55:791–800.
Yadav R, Saini A, Kaur P, Behera D, Sethi S. Diagnostic accuracy of GenoType® MTBDRsl VER 2.0 in detecting second-line drug resistance to M. tuberculosis. Int J Tuberc Lung Dis 2018;22:419–24.
Levin W, Brandon GR, McMillen S. The culture method of laboratory diagnosis of tuberculosis. Am J Public Health Nations Health 1950;40:1305–10.
Parmar MM, Sachdeva KS, Dewan PK, Rade K, Nair SA, Pant R, et al. Unacceptable treatment outcomes and associated factors among India’s initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007–2011): evidence leading to policy enhancement. PLoS One 2018;13:e0193903.
Paramasivan CN, Rehman F, Wares F, Sundar Mohan N, Sundar S, Devi S, et al. First- and second-line drug resistance patterns among previously treated tuberculosis patients in India. Int J Tuberc Lung Dis 2010;14:243–6.
Ho J, Jelfs P, Sintchenko V. Fluoroquinolone resistance in non-multidrug-resistant tuberculosis—a surveillance study in New South Wales, Australia, and a review of global resistance rates. Int J Infect Dis 2014;26:149–53.
Singhal P, Dixit P, Singh P, Jaiswal I, Singh M, Jain A. A study on pre-XDR & XDR tuberculosis & their prevalent genotypes in clinical isolates of Mycobacterium tuberculosis in north India. Indian J Med Res 2016;143:341–7.
Gao Y, Zhang Z, Deng J, Mansjö M, Ning Z, Li Y, et al. Multi-center evaluation of GenoType MTBDRsl line probe assay for rapid detection of pre-XDR and XDR Mycobacterium tuberculosis in China. J Infect 2018;77:328–34.
Jain A, Dixit P, Prasad R. Pre-XDR & XDR in MDR and ofloxacin and kanamycin resistance in non-MDR Mycobacterium tuberculosis isolates. Tuberculosis (Edinb) 2012;92:404–6.
Ramachandran R, Nalini S, Chandrasekar V, Dave PV, Sanghvi AS, Wares F, et al. Surveillance of drug-resistant tuberculosis in the state of Gujarat, India. Int J Tuberc Lung Dis 2009;13:1154–60.
Report of the First National Anti-tuberculosis Drug Resistance Survey. Central TB division, India 2018. Available from: https://tbcindia.gov.in/showfile.php?lid=3315
Lange C, Chesov D, Heyckendorf J, Leung CC, Udwadia Z, Dheda K. Drug-resistant tuberculosis: an update on disease burden, diagnosis and treatment. Respirology 2018;23:656–73.
Sharma AK, Gupta N, Kala DK, Patni T, Dixit R, Verma S, Chandran A. A study on pattern of resistance to second line anti tubercular drugs among multi drug resistant tuberculosis patients. Indian J Tuberc 2018;65:233–6.
Author information
Authors and Affiliations
Corresponding author
Additional information
First two authors are joint first author.
Rights and permissions
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
About this article
Cite this article
Sethi, S., Agarwal, P., Khaneja, R. et al. Second-line Drug Resistance Characterization in Mycobacterium tuberculosis by Genotype MTBDRsl Assay. J Epidemiol Glob Health 10, 42–45 (2020). https://doi.org/10.2991/jegh.k.191215.003
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2991/jegh.k.191215.003